PatentsDB

Untargeted and targeted IL-10 Fc-fusion proteins

US12006345B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12006345-B2
Application numberUS-202016798247-A
CountryUS
Kind codeB2
Filing dateFeb 21, 2020
Priority dateFeb 21, 2019
Publication dateJun 11, 2024
Grant dateJun 11, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.

First claim

Opening claim text (preview).

What is claimed is: 1. A composition comprising a variant interleukin-10 (IL-10) monomer domain consisting of a parent IL-10 monomer domain with an amino acid substitution or a set of amino acid substitutions, wherein the parent IL-10 monomer domain is SEQ ID NO:3 or SEQ ID NO:4; wherein the amino acid substitution or the set of amino acid substitutions are selected from the group consisting of: N21D, D28N, Q38E, Q42E, D44N, N45D, E142Q, D144N, E151Q, Q38E/D41N, Q38E/Q42E, Q38E/N45D, Q38E/E142Q, Q38E/D144N, D41N/Q42E, D41N/N45D, D41N/E142Q, D41N/D144N, Q42E/N45D, Q42E/E142Q, Q42E/D144N, N45D/E142Q, N45D/D144N, E142Q/D144N, N21D/Q42E, N21D/N45D, N21D/E151Q, N21D/N45E, Q42E/E151Q, N45D/E151Q, N21D/Q42E/N45D, N21D/Q42E/E151Q, Q42E/N45D/E151Q, N21D/Q42E/N45E, and N21D/Q42E/N45D/E151Q of SEQ ID NO:3 or SEQ ID NO:4. 2. The composition of claim 1 , wherein the variant IL-10 monomer domain comprises a set of amino acid substitutions selected from the group consisting of Q38E/D41N, Q38E/Q42E, Q38E/N45D, Q38E/E142Q, Q38E/D144N, D41N/Q42E, D41N/N45D, D41N/E142Q, D41N/D144N, Q42E/N45D, Q42E/E142Q, Q42E/D144N, N45D/E142Q, N45D/D144N, E142Q/D144N, N21D/Q42E, N21D/N45D, N21D/E151Q, N21D/N45E, Q42E/E151Q, N45D/E151Q, N21D/Q42E/N45D, N21D/Q42E/E151Q, Q42E/N45D/E151Q, N21D/Q42E/N45E, and N21D/Q42E/N45D/E151Q. 3. The composition of claim 1 , wherein the amino acid substitution or set of amino acid substitutions is selected from the group consisting of N45D, N45D/D144N, and Q38E/N45D of SEQ ID NO:3 or SEQ ID NO:4. 4. The composition of claim 1 , wherein the variant IL-10 monomer domain comprises the amino acid sequence of SEQ ID NO:562. 5. The composition of claim 1 , wherein the variant IL-10 monomer domain comprises the amino acid sequence of SEQ ID NO:568. 6. The composition of claim 1 , wherein the variant IL-10 monomer domain comprises the amino acid sequence of SEQ ID NO:571. 7. The composition of claim 1 , wherein the variant IL-10 monomer domain comprises the amino acid sequence of SEQ ID NO:132. 8. The composition of claim 1 , wherein the variant IL-10 monomer domain comprises the amino acid sequence of SEQ ID NO:139. 9. The composition of claim 1 , wherein the variant IL-10 monomer domain comprises the amino acid sequence of SEQ ID NO:150. 10. The composition of claim 1 , wherein the variant IL-10 monomer domain comprises the amino acid sequence of SEQ ID NO:171. 11. The composition of claim 1 , wherein the variant IL-10 monomer domain comprises the amino acid sequence of SEQ ID NO:178. 12. The composition of claim 1 , wherein the variant IL-10 monomer domain comprises the amino acid sequence of SEQ ID NO:189. 13. The composition of claim 1 , wherein the amino acid substitution or set of amino acid substitutions are selected from the group consisting of N21D, Q38E, Q42E, N45D, E142Q, E151Q, Q38E/D41N, Q38E/Q42E, Q38E/N45D, Q38E/E142Q, Q38E/D144N, D41N/Q42E, D41N/N45D, D41N/E142Q, D41N/D144N, Q42E/N45D, Q42E/E142Q, Q42E/D144N, N45D/E142Q, N45D/D144N, E142Q/D144N, N21D/Q42E, N21D/N45D, N21D/E151Q, N21D/N45E, Q42E/E151Q, N45D/E151Q, N21D/Q42E/N45D, N21D/Q42E/E151Q, Q42E/N45D/E151Q, N21D/Q42E/N45E, and N21D/Q42E/N45D/E151Q of SEQ ID NO:3 or SEQ ID NO:4.

Assignees

Inventors

Classifications

  • C07K2319/30

    Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

  • C12N2510/00

    Genetically modified cells · CPC title

  • C12N2800/107

    for mammalian · CPC title

  • C12N5/0686

    Kidney cells · CPC title

  • C12N15/85

    for animal cells · CPC title

Patent family

Related publications grouped by family.

View patent family 69960732

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12006345B2 cover?
The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.
Who is the assignee on this patent?
Xencor Inc
What technology area does this patent fall under?
Primary CPC classification C07K14/5428. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).